[Clinical studies of S-1108 fine granules in pediatrics].

Abstract

We have evaluated S-1108 fine granules for therapeutic effectiveness in children. The results are summarized as follows. 1. A clinical study was performed with 16 children with infections, including 8 with acute tonsillitis, 3 with acute pharyngitis, 2 with scarlet fever, 1 each with acute bronchitis, pertussis and urinary tract infection. Doses ranging from 8.8 to 10.6 mg/kg body weights were given in 3 divided portions. Durations of treatment ranged from 2 to 15 days. The therapeutic responses were considered "excellent" in 1 and "good" in 13, with an efficacy rate of 87.5%, and the bacteriological eradication rate was 91%. 2. No adverse reactions were observed. In laboratory tests, eosinophilia was observed in one patient. It was concluded the S-1108 was promising drug for the treatment of bacterial infections in children.

• Authors: H Morita, Y Morisawa, F Hamada, T Kurashige
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 46 Issue 12 Pg. 1107-13 (Dec 1993) ISSN: 0368-2781 [Print] Japan
• PMID: 8107275 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Cephalosporins
• Prodrugs
• S 1108

Topics

• Administration, Oral
• Cephalosporins (administration & dosage)
• Child
• Child, Preschool
• Female
• Humans
• Male
• Prodrugs (administration & dosage)
• Respiratory Tract Infections (drug therapy)
• Urinary Tract Infections (drug therapy)